bitop AG receives Frost & Sullivan’s 2013 New Product Innovation Award for its Ectoin Allergy products
Frost & Sullivan grants the 2013 European New Product Innovation Award in Extremolytes Therapeutics to bitop AG. The benchmark by Frost & Sullivan indicates that bitop AG has made available ectoin, one of the most commonly found extremolytes in nature, for human use.
bitop AG has explored and validated
Ectoin as a naturally-derived ingredient to alleviate and treat symptoms of allergic diseases as allergic rhinitis or conjunctivitis. Additional benefits of Ectoin can be achieved in the treatment of atopic dermatitis, dryness of the mucosa in the nose and of the conjunctiva in the eye while suffering from sicca syndromes and the reduction of common symptoms of cough and cold.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.